<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036486</url>
  </required_header>
  <id_info>
    <org_study_id>T3221</org_study_id>
    <nct_id>NCT05036486</nct_id>
  </id_info>
  <brief_title>The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer</brief_title>
  <official_title>The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Medical University Shuang Ho Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Koo Foundation Sun Yat-Sen Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biliary tract cancer (BTC) compromises a heterogenous group of tumors with poor prognoses.&#xD;
      Curative surgery remains the first choice for localized disease; however, most BTC patients&#xD;
      had unresectable or metastatic disease. The gold standard therapy for these patients is&#xD;
      chemotherapy with gemcitabine and cisplatin. There are no consensus guidelines for standard&#xD;
      treatment in a second-line setting, although the data of the ABC-06 trial showed a slight&#xD;
      survival benefit from oxaliplatin and 5-fluorouracil combination chemotherapy.&#xD;
&#xD;
      Recent progress in comprehensive genomic profiling for advanced BTC has helped to clarify&#xD;
      tumorigenesis and facilitate the coming era of precision medicine. To further elucidate the&#xD;
      underlying molecular genomic aberrations, as well as the clinical demographics and&#xD;
      therapeutic outcomes, it is necessary to have a national, multi-centers and&#xD;
      population-focused research project to collect data completely. Tumor tissue will be&#xD;
      collected from advanced BTC patients for real-time next-generation sequencing analysis in a&#xD;
      platform of data storage and sharing. The purpose of the precision medicine project is to&#xD;
      establish tumor molecular profiling of BTC populations in Taiwan, to facilitate patients to&#xD;
      have corresponding potential targeted therapeutics and suitable clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>To enroll 200 patients who fit the criteria of this study in the enrolled period</measure>
    <time_frame>5 years</time_frame>
    <description>To enroll 200 patients who fit the criteria of this study in the enrolled period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To perform large-scale NGS analysis for specific populations</measure>
    <time_frame>5 years</time_frame>
    <description>To create a map containing important genetic characteristics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect clinical data of Biliary tract cancer patients</measure>
    <time_frame>5 years</time_frame>
    <description>Collect clinical data of Biliary tract cancer patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the clinical characteristics, treatment and outcome of Biliary tract cancer with the genetic profile in Taiwan.</measure>
    <time_frame>5 years</time_frame>
    <description>To correlate the clinical characteristics, treatment and outcome of Biliary tract cancer patients</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Biliary Tract Cancer (BTC)</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>next-generation sequencing</intervention_name>
    <description>Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Oncopanel test&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        treatment naïve or under 1 st line therapy, metastatic or unresectable population s ,&#xD;
        clinical information , and therapeutic outcomes in advanced BTC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 20 and above.&#xD;
&#xD;
          2. Pathological reported showed adenocarcinoma or adenosquamous carcinoma for patients&#xD;
             with Biliary tract cancer (include intrahepatic cholangiocarcinoma (IHCC),&#xD;
             extrahepatic cholangiocarcinoma (EHCC), gallbladder cancer (GBC) and ampulla of Vater&#xD;
             cancer (AVC) ) or hepatocholangiocarcinoma.&#xD;
&#xD;
          3. Willingness to provide the residual biopsy/operative slides.&#xD;
&#xD;
          4. Life expectancy more than 3 months.&#xD;
&#xD;
          5. Patients fully understand the protocol with the willingness to have regular follow-up.&#xD;
&#xD;
          6. Patients are systemic treatment-naïve or under 1st line therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to cooperate by providing a complete medical history.&#xD;
&#xD;
          2. No available tumor tissues for genetic testing.&#xD;
&#xD;
          3. Undesirable compliance.&#xD;
&#xD;
          4. Other malignancy within the past 1 years except adequately treated basal or squamous&#xD;
             cell skin cancer or cervical cancer in situ.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Tzong Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Health Research Institutes, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Huang Chen, MD, PhD</last_name>
    <phone>886-2-28757270</phone>
    <email>mhchen9@vghtpe.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nai-Jung Chiang, MD, PhD</last_name>
    <phone>886-7000123 ext 65148</phone>
    <email>njchiang@nhri.edu.tw</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biliary tract cancer</keyword>
  <keyword>Next-generation sequencing</keyword>
  <keyword>precision medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

